Zacks Investment Research cut shares of BioSpecifics Technologies (NASDAQ:BSTC) from a buy rating to a hold rating in a research note released on Friday.
According to Zacks, “BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals. “
Other equities research analysts also recently issued reports about the company. HC Wainwright reissued a buy rating on shares of BioSpecifics Technologies in a report on Tuesday, December 26th. decreased their price objective on BioSpecifics Technologies from $72.00 to $65.00 and set a buy rating for the company in a report on Wednesday, November 15th.
BioSpecifics Technologies (NASDAQ:BSTC) last posted its quarterly earnings data on Friday, November 10th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.01. The business had revenue of $6.52 million during the quarter, compared to the consensus estimate of $6.59 million. BioSpecifics Technologies had a return on equity of 19.11% and a net margin of 42.40%. equities analysts forecast that BioSpecifics Technologies will post 1.57 EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of BSTC. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of BioSpecifics Technologies in the third quarter valued at approximately $223,000. SG Americas Securities LLC acquired a new stake in shares of BioSpecifics Technologies during the second quarter worth $241,000. The Manufacturers Life Insurance Company lifted its holdings in shares of BioSpecifics Technologies by 9.1% during the second quarter. The Manufacturers Life Insurance Company now owns 4,920 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 410 shares during the period. Rhumbline Advisers lifted its holdings in shares of BioSpecifics Technologies by 7.5% during the second quarter. Rhumbline Advisers now owns 6,667 shares of the biopharmaceutical company’s stock worth $330,000 after purchasing an additional 466 shares during the period. Finally, Teachers Advisors LLC lifted its holdings in shares of BioSpecifics Technologies by 14.8% during the second quarter. Teachers Advisors LLC now owns 10,098 shares of the biopharmaceutical company’s stock worth $500,000 after purchasing an additional 1,305 shares during the period. 55.93% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Lowers BioSpecifics Technologies (BSTC) to Hold” was first published by Week Herald and is the property of of Week Herald. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://weekherald.com/2018/01/15/zacks-investment-research-lowers-biospecifics-technologies-bstc-to-hold.html.
About BioSpecifics Technologies
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.